Valneva SE

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision

22 янв 2025 10:45:00 Источник Nasdaq GlobeNewswire

Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine

20 янв 2025 10:45:00 Источник Nasdaq GlobeNewswire

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference

06 янв 2025 10:45:00 Источник Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: December 31, 2024

03 янв 2025 11:00:00 Источник Nasdaq GlobeNewswire

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India

19 дек 2024 01:00:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: November 30, 2024

05 дек 2024 00:30:00 Источник Nasdaq GlobeNewswire

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal

04 дек 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

03 дек 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA

26 ноя 2024 10:45:00 Источник Nasdaq GlobeNewswire

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2

13 ноя 2024 10:45:00 Источник Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

12 ноя 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates

07 ноя 2024 00:00:00 Источник Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2024

06 ноя 2024 01:30:00 Источник Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

21 окт 2024 10:45:00 Источник Nasdaq GlobeNewswire

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

16 окт 2024 10:45:00 Источник Nasdaq GlobeNewswire

Valneva Hosts Investor Day in New York City

10 окт 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva SE - Declaration of shares and voting rights - September 30, 2024

04 окт 2024 00:30:00 Источник Nasdaq GlobeNewswire

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET

03 окт 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada

18 сен 2024 00:00:00 Источник Nasdaq GlobeNewswire

Valneva Announces the Success of its Private Placement Raising approximately €60 Million

13 сен 2024 01:30:00 Источник Nasdaq GlobeNewswire